Introduction
Diabetic foot ulceration, a common complication of diabetes, has emerged as a significant burden to the health care industry. 1 Clinical observations have indicated that treatment options for diabetic ulcers are insufficient in many cases, and disease progression can ultimately lead to limb amputation. Therefore, a detailed understanding of the pathobiology of diabetic refractory ulcers is necessary. A number of pathophysiologic changes are considered to be responsible for impaired wound healing of diabetic patients. Many researchers have indicated that a retarded remodeling process is caused by abnormally elevated levels of a matrix metalloproteinase (MMP), a superfamily of proteases that can degrade various kinds of extracellular matrix. [2] [3] [4] In nondiabetic wounds, MMPs are important for remodeling defective tissues by increasing the migration of fibroblasts and endothelial cells of the connective tissues. Their expression levels are tightly
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li et al controlled to remove denatured fibrillar collagen and assist proper development of granulation tissues during the woundhealing process. Their activities are increased in the early healing phase and then decreased as the healing process completes. Abnormal expression of MMPs, especially MMP-9, in chronic diabetic wounds, has been previously studied. 5, 6 Our previous comparative study analyzed the dynamic changes of MMP-9 expression in skin wounds of diabetic and nondiabetic rats, and showed that high expression and activity of MMP-9 contributed to delayed healing at the late stage of wound healing (after the seventh day) much more than at the early stage (before the third day). 7 In 2009, Liu et al 8 reported that a high MMP-9 expression level in diabetic wound exudates was predictive of poor wound healing. A subsequent study in a murine model of wound healing further supported the concept that MMP-9 delayed the wound-healing process. 9 Consequently, the breakdown rates of matrix proteins such as collagen and elastin override the remodeling rates of the defected tissues because of the higher activities of MMP-9. Many growth factors, including epidermal growth factor and basic fibroblast growth factor, showed limited effectiveness toward highly active MMP-9 and other hydrolytic enzymes. [10] [11] [12] Therefore, the direct inhibition of MMP-9 through RNA interference (RNAi) may represent a feasible strategy by which to improve chronic wound healing.
Since its first report in 1998, RNAi has rapidly become a powerful strategy both in basic research and in the development of efficient therapeutics. 13, 14 RNAi is a process by which RNA molecules, with sequences complementary to a gene's coding sequence, induce the degradation of corresponding messenger RNAs (mRNAs), thus blocking the translation of the mRNA into protein. 15, 16 RNAi is initiated by exposing cells to a long double-stranded RNA via transfection or endogenous expression. dsRNAs are processed into smaller fragments (typically 21-23 nucleotides) of small interfering RNAs (siRNAs), 17 which form a complex with the RNAinduced silencing complexes. 18 The introduction of siRNA into mammalian cells leads to the downregulation of target genes without triggering interferon responses. 17 Gene therapy using siRNA has shown great potential for diseases caused by abnormal gene expression or mutation. [19] [20] [21] One difficulty that gene therapy strategies encounter is the need for an efficient, easy, and minimally toxic mode of siRNA delivery to cells. [22] [23] [24] Cationic star-shaped polymers based on cyclodextrins (CDs) have recently attracted considerable attention as nonviral gene carriers due to their dense molecular architecture with moderate flexibility. 25 It is known 26 that CDs have low immunogenicity and toxicity and can enhance the absorption and resistance to nucleases through binding and interacting with oligonucleotides. In this context, Xu et al 27 designed the cationic star-shaped polymers consisting of a β-CD core and poly(2-(dimethylamino)ethyl methacrylate) or its block copolymer arms, and Srinivasachari et al 28 reported on a series of multivalent polycationic "click clusters" based on a β-CD core and oligoethyleneamine arms.
In this study, a cationic star-shaped polymer consisting of a β-CD core and poly(amidoamine) dendron arms, namely β-CD-(D 3 ) 7 , was explored for the first time as a carrier of MMP-9-siRNA to suppress MMP-9 expression in rat fibroblast cells via RNAi. In particular, animal experiments were performed to demonstrate the efficacy of β-CD-(D 3 ) 7 /MMP-9-siRNA complexes in decreasing MMP-9 expression and promoting wound healing in diabetic skin tissues.
Materials and methods Materials
β-CD-(D 3 ) 7 was synthesized in our lab by the click conjugation of per-6-azido-β-CD with propargyl focal point poly(amidoamine) dendron (D 3 , third generation), as reported in our previous publication. 29 Lipofectamine ® 2000 was purchased from Thermo Fisher Scientific (Waltham, MA, USA). MMP-9-siRNA was purchased from Shanghai GenePharma Co., Ltd., Shanghai, People's Republic of China. Sprague Dawley rats weighing 250-300 g were obtained from the Experimental Animal Center of Sun Yat-sen University (Guangzhou, People's Republic of China). All care and handling of the animals was per formed in accordance with the requirements of the Experimental Animal Center of Sun Yat-sen University. All other reagents were of ana lytical or high-performance liquid chromatography grade.
Preparation and characterization of β-cD-(D 3 ) 7 /MMP-9-sirNa complexes
The β-CD-(D 3 ) 7 /MMP-9-siRNA complexes were prepared at various charge ratios by mixing equal volumes of β-CD-(D 3 ) 7 with MMP-9-siRNA in phosphate-buffered saline. The charge ratio (amino group to phosphate group [N/P]) was calculated as a ratio of the number of primary amines in the polymer to the number of anionic phosphate groups in the MMP-9-siRNA. The samples were then vortexed and incubated at 37°C for 15 minutes to ensure formation of the complex. For the resultant β-CD-(D 3 ) 7 /MMP-9-siRNA complexes, their particle sizes in aqueous system were measured at 25°C using a ZetaPALS zeta potential analyzer (Brookhaven Instruments Corporation, Holtsville, NY, USA). Their morphology was observed using transmission electron microscopy (TEM) (JEM2010; JEOL, Tokyo, Japan). cell viability assay 7 . After 24, 48, or 72 hours, the cells were incubated in the dark with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution for 4 hours at 37°C. After the supernatants were aspirated, dimethyl sulfoxide was added to each well, and the plates were agitated to dissolve the formazan crystal product. The absorbance at 492 nm was then measured using a microplate reader (Wellscan MK3, Labsystems Ltd. OY, Vantaa, Finland). The cell viability was calculated according to the following formula (with "A" showing absorbance):
The experiment was repeated three times.
agarose gel electrophoresis
The ability of β-CD-(D 3 ) 7 to complex MMP-9-siRNA was examined via gel electrophoresis (AlphaImager HP, ProteinSimple, Santa Clara, CA, USA). For this purpose, β-CD-(D 3 ) 7 /MMP-9-siRNA complexes with N/P ratios of 40:1, 30:1, 20:1, or 10:1 were formed. Negative control complexes were also generated (by incubating MMP-9-siRNA in the absence of β-CD-[D 3 ] 7 ). After incubation for 15 minutes at room temperature, MMP-9-siRNA complexation was studied via agarose gel retardation assays. The samples were electrophoresed in a 4% agarose gel at 80 V for 20 minutes. MMP-9-siRNA was visualized using an ultraviolet transilluminator (AlphaImager HP, ProteinSimple, Santa Clara, CA, USA).
In vitro transfection experiment
Fibroblast cells were seeded in 24-well plates (Corning Incorporated, Corning, NY, USA) at an initial density of 1×10 5 cells per well in 0.5 mL medium. After culturing for 12 hours, the cell culture medium was replaced with serum-free medium (opti-MEM; Thermo Fisher Scientific). β-CD-(D 3 ) 7 /MMP-9-siRNA complexes were formed at different mass ratios (40:1, 30:1, 20:1, 10:1, and 4:1). At all ratios, carboxyfluorescein-labeled siRNA was used at a fixed final concentration of 40 nmol/L. The cells were incubated with the complexes in serum-free culture medium for 4 hours at 37°C. Then, the medium was replaced with fresh medium containing 10% serum, and the cells were incubated for 24 hours. The transfection efficiency of the β-CD-(D 3 ) 7 /MMP-9-siRNA complexes was determined via confocal microscopy (LSM 510 META; Carl Zeiss Meditec AG, Jena, Germany) and flow cytometry (FACSCalibur TM ; BD Biosciences, San Jose, CA, USA). The percentages of dead cells after transfection were also evaluated via flow cytometry. The transfection efficiency of the commercially available transfection reagent Lipofectamine 2000 was also evaluated. The experiment was repeated three times.
establishment of an MMP-9 overexpressing cell model
Fibroblast cells were seeded in six-well plates at an initial density of 3×10 5 cells per well. After 24 hours, the cell culture medium was replaced with medium supplemented with 0.5% FBS for cell synchronization. After 24 hours, the culture medium was replaced with fresh culture medium containing 25 mmol/L glucose; 1 µg/mL lipopolysaccharide was also added for 18 hours to stimulate MMP-9 expression. Cells cultured in medium containing 25 mmol/L glucose alone were used as control. Quantitative real time (RT) polymerase chain reaction was performed to determine the level of MMP-9 gene expression. 
Inhibition effect on MMP-9 expression
Diabetic models
Sprague Dawley rats weighing 250-300 g were used for these experiments. Diabetes was induced via a single intraperitoneal injection of freshly dissolved streptozocin (50 mg/kg of body weight; Sigma-Aldrich Co., St Louis, MO, USA) in 0.1 mol/L citrate buffer (pH 4.5). Three days after streptozocin injection, the serum glucose levels of the rats were examined. Rats displaying random blood glucose levels 16.7 mmol/L were considered diabetic and were selected for further experimentation.
Full-thickness skin wound preparation
Six weeks after modeling, rats were anesthetized using ethyl ether. Their dorsal hair was shaved using an electric clipper, and the surgical areas were disinfected with an alcohol/iodine solution. A sterile template 1.8 cm in diameter was placed on each side of the mid-back, and a full-thickness wound to the deep fascia corresponding to the size of the template was generated by excising the skin. The wounding day was considered as day 0.
animal grouping and interventions
Twenty diabetic rats were randomly separated into four groups (n=5): 1) the diabetic group, consisting of untreated wounded diabetic rats; 2) the MMP-9-siRNA control group, consisting of wounded diabetic rats treated with MMP-9-siRNA solution; 3) the β-CD-(D 3 ) 7 group, consisting of wounded diabetic rats treated with β-CD-(D 3 ) 7 solution; and 4) the β-CD-(D 3 ) 7 / MMP-9-siRNA group, consisting of wounded diabetic rats treated with β-CD-(D 3 ) 7 /MMP-9-siRNA complex solution. Each wound (1.8×1.8 cm) was made on the back of each rat by removing the whole skin, including the epidermis, dermis, and subcutaneous tissue, with surgical scissors.
Measurement of wound closure
The wounds on each rat were digitally photographed on days 0, 2, 4, 6, and 7. The wound size was calculated on days 4 and 7 using ImageJ software (v 1.36b; National Institutes of Health, Bethesda, MD, USA). The percentage of wound closure was calculated according to the following formula:
statistical analyses
The results were expressed as the means ± standard deviation, and the statistical software program SPSS (v 16.0; SPSS Inc., Chicago, IL, USA) was used to perform the calculations. Student's t-test (two-tailed) was used for statistical analyses, and analysis of variance was used for data subjected to multiple comparisons, followed by Bonferroni post hoc analysis comparisons between two groups. A P-value 0.05 was considered to be statistically significant.
Results and discussion
To investigate the cytotoxicity of β-CD-(D 3 ) 7 , cell viability was determined by the MTT method. Figure 1 shows the viability of fibroblast cells incubated with different concentrations (21.3 µg/mL, 16.0 µg/mL, 10.7 µg/mL, 5.3 µg/mL, or 2.1 µg/mL) of β-CD-(D 3 ) 7 for various amounts of time (24 hours, 48 hours, or 72 hours). As can be seen in Figure 1 , no significant difference in cell viability was observed between groups of fibroblast cells treated with different concentrations of β-CD-(D 3 ) 7 , regardless of incubation time. Compared to a commercially available poly(amidoamine) dendrimer (poly(amidoamine), G=4), which has been reported in the literature as a standard nonviral gene carrier with a maximum safe dosage of only 10 µg/mL, [30] [31] [32] β-CD-(D 3 ) 7 displayed much lower cytotoxicity. Moreover, the cell viability did not show mainly dose-dependent decrease nor mainly time-dependent increase. This could be attributed to the introduction of β-CD core with good biocompatibility, 33 which would be an advantage were β-CD-(D 3 ) 7 used as a carrier for the delivery of MMP-9-siRNA.
Formation of β-cD-(D 3 ) 7 /MMP-9-sirNa complexes
The ability of β-CD-(D 3 ) 7 to condense MMP-9-siRNA into particulate structures was confirmed by agarose gel electrophoresis, particle size measurements, and TEM observation. Figure 2A shows the electrophoretic mobility of MMP-9-siRNA in the complexes between β-CD-(D 3 ) 7 and MMP-9-siRNA at various ratios of amino group (in β-CD-(D 3 ) 7 ) to phosphate group (in MMP-9-siRNA), defined as N/P ratio. As can be seen in Figure 2A , the migration of MMP-9-siRNA in agarose gel was completely retarded when the N/P ratio was equal to or higher than 4. Therefore, β-CD-(D 3 ) 7 could combine MMP-9-siRNA and condense complexes into nanoparticles due to the relatively higher density of primary amino group.
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cationic star-shaped polymer as an sirNa carrier Figure 2B shows the particle size of β-CD-(D 3 ) 7 / MMP-9-siRNA complexes at various N/P ratios. It was found that β-CD-(D 3 ) 7 could efficiently compact MMP-9-siRNA into small nanoparticles. Moreover, the mean particle size decreased from 268 nm to 110 nm with the increase of N/P ratio from 6 to 60. Figure 2C gives a representative TEM image and particle size distribution for the β-CD-(D 3 ) 7 /MMP-9-siRNA complexes at the N/P ratio of 30. It was found that these complexes had a spherical morphology and a narrow particle size distribution.
Transfection efficiency of β-cD-(D 3 ) 7 / MMP-9-sirNa complexes
The transfection efficiency of β-CD-(D 3 ) 7 /MMP-9-siRNA complexes was investigated in fibroblast cells by confocal microscopy and flow cytometry. For a comparative 
Wound healing efficiency
To evaluate the wound healing efficiency, the skin wounds in diabetic models were treated for various amounts of time with buffer solution, MMP-9-siRNA alone, β-CD-(D 3 ) 7 alone, and β-CD-(D 3 ) 7 /MMP-9-siRNA complexes (mass ratio =20), respectively, as shown in Figure 7 . Figure 8 gives the wound-closure percentages in these cases. As can be seen in Figure 8 , the wound-closure percentage in the case of MMP-9-siRNA alone did not show an obvious increase when compared to the percentages in the cases of buffer solution or β-CD-(D 3 ) 7 alone. In contrast, the use of β-CD-(D 3 ) 7 /MMP-9-siRNA complexes resulted in enhanced wound healing, particularly after treatment for 7 days. This may be attributed to the inhibition of β-CD-(D 3 ) 7 /MMP-9-siRNA complexes to MMP-9 expression in fibroblast cells. In addition, the level of blood glucose in the experimental animals was found to be 30.3±3.79 mmol/L and 24.5±11.6 mmol/L (P0.05) before and after treatment with β-CD-(D 3 ) 7 /MMP-9-siRNA complexes, respectively. Further investigations will focus on the mechanism for enhanced wound healing in diabetic rats.
Conclusion
As a new cationic star-shaped polymer, β-CD-(D 3 ) 7 has good biocompatibility and strong complexation ability to 7 , a cationic star-shaped polymer consisting of a β-cyclodextrin core and poly(amidoamine) dendron arms; MMP-9, matrix metalloproteinase-9; sirNa, small interfering rNa. 
